Rhythm Pharmaceuticals (RYTM) Q4 FY25 earnings call

Rhythm Pharmaceuticals delivered a strong Q4 FY25, driven by robust IMCIVREE sales growth and significant progress in its pipeline, particularly with Bivamelagon's Phase 2 data supporting a move to Phase 3. The company is actively preparing for the acquired hypothalamic obesity launch, while also managing increased operating expenses for future investments. The FDA's requirement for a longer Bivamelagon Phase 3 trial highlights the regulatory hurdles for new chemical entities, but management remains confident in its long-term growth strategy.